According to EDAP TMS, the global leader in robotic ultrasound therapy, prostate micro-ultrasound and the Focal One robotic ultrasound therapy technology have now been introduced at the University of Washington School of Medicine (UW Medicine).
Focal One HIFU – robotic ultrasound therapy for prostate cancer – was first implemented simultaneously at the Karazanashvili Robotic Center and leading U.S. clinics such as the University of California San Francisco Medical Center and the Cleveland Clinic at the end of 2020. Now, UW Medicine, one of the world’s top-rated academic medical systems, has also launched a robotic ultrasound therapy program for the treatment of localized prostate cancer using the Focal One technology.
UW Medicine
Focal One HIFU (#focalone #HIFU) is a non-invasive, non-surgical, radiation-free, cutting-edge treatment for localized prostate cancer, developed by EDAP TMS SA, the internationally recognized leader in the global ultrasound therapeutic market.
Focal One HIFU by EDAP TMS
EDAP TMS develops, manufactures, promotes, and distributes minimally invasive medical devices for various pathologies using ultrasound technologies. With a full range of robotic ultrasound systems that combine advanced imaging and treatment models, EDAP TMS introduced Focal One® in Europe and the U.S. as the comprehensive answer to all requirements for optimal prostate tissue ablation.
With the integration of the ExactVu™ micro-ultrasound device, EDAP TMS has become the only company worldwide to offer a complete solution for 100% accurate diagnosis and effective treatment of prostate cancer, from screening to focal therapy.
EDAP TMS Website
U.S. Focal Therapy Site
“We are delighted that UW Medicine has chosen to offer Focal One HIFU to its patients,” said Marc Oczachowski, Chairman and CEO of EDAP, responding to the adoption of Focal One and prostate micro-ultrasound at the University of Washington. “Our technology is widely recognized by leading global academic medical centers in the field of urology as a key part of the most advanced and comprehensive prostate cancer treatment strategy.”
Globally, top urology centers are increasingly implementing focal therapy programs using Focal One technology. The improved visualization, combined with micro-ultrasound-guided targeted biopsies and energy-based treatment, has significantly expanded the use of focal treatment methods. These technologies have the potential to precisely target cancerous tissues while preserving healthy prostate and surrounding tissues—critical for maintaining quality of life in men.
As we can see, the Karazanashvili Robotic Center is one of the first urological clinics among global leaders to rapidly implement the most advanced technologies and services of modern medicine, ensuring maximum accessibility for patients.
It is also worth noting that, in addition to Focal One HIFU, the Karazanashvili Robotic Center—through the efforts of Professor Guram Karazanashvili—was the first in Georgia and the entire region (including Turkey, Russia, the South Caucasus, etc.) to introduce:
-
Prostate cancer screening and early diagnosis using micro-ultrasound
-
Targeted prostate biopsy under micro-ultrasound guidance
-
Fusion biopsy combining micro-ultrasound and MRI guidance
These are cutting-edge technologies that are only now being introduced in some of the world’s leading clinics.
